Principal Financial Group
NVCR icon

Principal Financial Group’s NovoCure NVCR Stock Holding History

Principal Financial Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9,134
Closed -$272K – 2206
2024
Q4 		$272K Buy
+9,134
New +$193K ﹤0.01% 2055
2024
Q3 		– Sell
-18,287
Closed -$313K – 2353
2024
Q2 		$313K Sell
18,287
-4,126
-18% -$72.6K ﹤0.01% 2050
2024
Q1 		$350K Sell
22,413
-1,886
-8% -$27.7K ﹤0.01% 2063
2023
Q4 		$363K Sell
24,299
-1,793
-7% -$24K ﹤0.01% 2019
2023
Q3 		$421K Buy
26,092
+1,539
+6% +$44.4K ﹤0.01% 1986
2023
Q2 		$1.02M Sell
24,553
-882
-3% -$54.8K ﹤0.01% 1842
2023
Q1 		$1.53M Sell
25,435
-2,951
-10% -$236K ﹤0.01% 1804
2022
Q4 		$2.08M Buy
28,386
+4,238
+18% +$319K ﹤0.01% 1755
2022
Q3 		$1.83M Sell
24,148
-4,107
-15% -$320K ﹤0.01% 1730
2022
Q2 		$1.96M Buy
28,255
+3,922
+16% +$295K ﹤0.01% 1810
2022
Q1 		$2.02M Sell
24,333
-1,480
-6% -$109K ﹤0.01% 1861
2021
Q4 		$1.94M Buy
25,813
+12,990
+101% +$1.3M ﹤0.01% 1860
2021
Q3 		$1.49M Sell
12,823
-580
-4% -$87.7K ﹤0.01% 1920
2021
Q2 		$2.97M Buy
13,403
+2,177
+19% +$423K ﹤0.01% 1826
2021
Q1 		$1.48M Sell
11,226
-956
-8% -$151K ﹤0.01% 1913
2020
Q4 		$2.11M Sell
12,182
-21,252
-64% -$2.91M ﹤0.01% 1788
2020
Q3 		$3.72M Sell
33,434
-2,737
-8% -$219K ﹤0.01% 1568
2020
Q2 		$2.15M Buy
36,171
+12,570
+53% +$827K ﹤0.01% 1683
2020
Q1 		$1.59M Sell
23,601
-2,820
-11% -$223K ﹤0.01% 1655
2019
Q4 		$2.23M Buy
26,421
+1,814
+7% +$146K ﹤0.01% 1708
2019
Q3 		$1.84M Sell
24,607
-1,152
-4% -$92.1K ﹤0.01% 1731
2019
Q2 		$1.63M Sell
25,759
-18,376
-42% -$931K ﹤0.01% 1757
2019
Q1 		$2.13M Buy
44,135
+1,731
+4% +$83.3K ﹤0.01% 1730
2018
Q4 		$1.42M Sell
42,404
-15,420
-27% -$564K ﹤0.01% 1767
2018
Q3 		$3.03M Buy
57,824
+4,476
+8% +$178K ﹤0.01% 1708
2018
Q2 		$1.67M Buy
53,348
+8,499
+19% +$236K ﹤0.01% 1774
2018
Q1 		$978K Buy
44,849
+4,106
+10% +$88.3K ﹤0.01% 1831
2017
Q4 		$823K Buy
+40,743
New +$785K ﹤0.01% 1876

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Principal Financial Group's NVCR Position: Q1 2025 in Review

Principal Financial Group sold out of NovoCure (NVCR) in Q1 2025, closing a stake of 9,134 shares — an estimated $272K sold.

Principal Financial Group first reported a position in NVCR in Q4 2017 and held it in 28 quarters. The position peaked at $3.72M in Q3 2020. 227 funds tracked by Wall St. Rank hold NVCR as of Q1 2025.

  • Principal Financial Group reported no remaining NovoCure position as of Q1 2025 after selling out during the quarter.
  • Principal Financial Group sold 9,134 NovoCure shares in Q1 2025, an estimated $272K.
  • Principal Financial Group first reported a position in NovoCure in Q4 2017 and held it in 28 quarters.
  • Principal Financial Group's NovoCure position peaked at $3.72M in Q3 2020.
  • 227 funds tracked by Wall St. Rank held NovoCure as of Q1 2025.

Based on Principal Financial Group's 13F filing for Q1 2025, filed 28 Apr 2025.